Tag: cse:lxx
May 15, 2019
Lexaria’s DehydraTECHTM Formulation Delivers 475% More CBD to Bloodstream after 15 Minutes than Conventional Industry Formulations
Lexaria Bioscience Corp. (CSE:LXX, OTCQX:LXRP) (the "Company" or "Lexaria"), a drug delivery platform innovator, has proven in animal testing that... May 7, 2019
Lexaria Bioscience Announces CBD-Beverage Formulation License Agreement with Nevada-Based Company
Lexaria Bioscience Corp. (CSE:LXX, OCTQX:LXRP) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces that it has entered a... April 25, 2019
Lexaria Bioscience Expands Advisory Board
Lexaria Bioscience Corp. (CSE:LXX, OCTQX:LXRP) (the "Company" or "Lexaria"), a drug delivery platform innovator, is pleased to announce new appointments... April 24, 2019
Lexaria Bioscience Announces Beverage License Agreement with California-Based Cannabis Company
Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) announces that it has entered a definitive 5-year agreement, via its subsidiary Lexaria... April 9, 2019
Lexaria Bioscience Renews Contracts with Senior Management and Cancels Options
Lexaria Bioscience Corp. (CSE:LXX, OTCQX:LXRP) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, announces that it has successfully negotiated...
February 26, 2019
Lexaria Bioscience Comments on FDA Statement on Novel Nicotine Replacement Therapies
Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, comments on the February 21, 2019... February 21, 2019